Tìm theo
Valrubicin
Các tên gọi khác (7 ) :
  • (8S, 10S)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-(2,2,2-trifluoroacetamido)-α-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione 8²-valerate
  • 2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-({2,3,6-trideoxy-3-[(trifluoroacetyl)amino]hexopyranosyl}oxy)-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
  • Valrubicin
  • Valrubicina
  • Valrubicine
  • Valrubicinum
  • Valstar
Thuốc Gốc
Small Molecule
CAS: 56124-62-0
ATC: L01DB09
ĐG : Endo Pharmaceuticals Inc. , http://www.endo.com
CTHH: C34H36F3NO13
PTK: 723.6437
Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. [Wikipedia]
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C34H36F3NO13
Phân tử khối
723.6437
Monoisotopic mass
723.213874858
InChI
InChI=1S/C34H36F3NO13/c1-4-5-9-21(40)49-13-20(39)33(47)11-16-24(19(12-33)51-22-10-17(27(41)14(2)50-22)38-32(46)34(35,36)37)31(45)26-25(29(16)43)28(42)15-7-6-8-18(48-3)23(15)30(26)44/h6-8,14,17,19,22,27,41,43,45,47H,4-5,9-13H2,1-3H3,(H,38,46)/t14?,17?,19-,22?,27?,33-/m0/s1
InChI Key
InChIKey=ZOCKGBMQLCSHFP-ZQUOIQDWSA-N
IUPAC Name
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-{[5-hydroxy-6-methyl-4-(trifluoroacetamido)oxan-2-yl]oxy}-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl]ethyl pentanoate
Traditional IUPAC Name
2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-4-{[5-hydroxy-6-methyl-4-(trifluoroacetamido)oxan-2-yl]oxy}-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl pentanoate
SMILES
CCCCC(=O)OCC(=O)[C@@]1(O)C[C@H](OC2CC(NC(=O)C(F)(F)F)C(O)C(C)O2)C2=C(C1)C(O)=C1C(=O)C3=C(C(=O)C1=C2O)C(OC)=CC=C3
Độ tan chảy
116-117 °C
Độ hòa tan
insoluble
logP
2.2
logS
-4.3
pKa (strongest acidic)
5.39
pKa (Strongest Basic)
-3.4
PSA
215.22 Å2
Refractivity
168.03 m3·mol-1
Polarizability
68.86 Å3
Rotatable Bond Count
12
H Bond Acceptor Count
12
H Bond Donor Count
5
Physiological Charge
-1
Number of Rings
5
Bioavailability
0
MDDR-Like Rule
true
Dược Lực Học : Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder.
Cơ Chế Tác Dụng : Valrubicin (N-trifluoroacetyladriamycin-14-valerate, Valstar®) is a chemotherapy drug used to treat bladder cancer. Valrubicin is a semisynthetic analog of the anthracycline doxorubicin, and is administered by infusion directly into the bladder. [Wikipedia] Valrubicin is an anthracycline that affects a variety of inter-related biological functions, most of which involve nucleic acid metabolism. It readily penetrates into cells, where after DNA intercalation, it inhibits the incorporation of nucleosides into nucleic acids, causes extensive chromosomal damage, and arrests cell cycle in G2. Although valrubicin does not bind strongly to DNA, a principal mechanism of its action, mediated by valrubicin metabolites, is interference with the normal DNA breaking-resealing action of DNA topoisomerase II.
Dược Động Học :

▧ Protein binding :
>99%
▧ Metabolism :
Valrubicin is metabolized to two primary metabolites: N-trifluoroacetyladriamycin and N-trifluoroacetyladriamycinol.
Độc Tính : The primary anticipated complications of overdosage associated with intravesical administration would be consistent with irritable bladder symptoms. Myelosuppression is possible if valrubicin is inadvertently administered systemically or if significant systemic exposure occurs following intravesical administration (e.g., in patients with bladder/rupture perforation). The maximum tolerated dose in humans by either intraperitoneal or intravenous administration is 600 mg/m2.
Chỉ Định : For the treatment of cancer of the bladder.
Tương Tác Thuốc :
  • Docetaxel The taxane derivative, Docetaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
  • Natalizumab Valrubicin may increase Natalizumab toxicity. Concurrent therapy should be avoided.
  • Paclitaxel The taxane derivative, Paclitaxel, may increase Valrubicin toxicity. Consider alternate therapy or monitor for toxic effects.
  • Trastuzumab Trastuzumab may increase the cardiotoxicity of Valrubicin. Signs and symptoms of cardiac dysfunction should be monitored for frequently. Increased risk of heart failure. Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Liquid - Intravesical
Dữ Kiện Thương Mại
Giá thị trường
  • Biệt dược thương mại : Valstar 40 mg/ml vial
    Giá bán buôn : USD >219.96
    Đơn vị tính : ml
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00385
PubChem Compound
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=41744
PubChem Substance
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506642
ChemSpider
http://www.chemspider.com/Chemical-Structure.38088.html
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/67979-001-01
PharmGKB
http://www.pharmgkb.org/drug/PA164748616
Wikipedia
http://en.wikipedia.org/wiki/Valrubicin
RxList
http://www.rxlist.com/cgi/generic2/rubicin.htm
Drugs.com
http://www.drugs.com/cdi/valrubicin.html
... loading
... loading